powered by centersite dot net
Medications
Resources
Basic InformationLatest News
When Is an Opioid Safe to Take?Lifesaving Drugs From Pfizer in Short Supply: FDALeading U.S. Doctors' Group Takes Aim at Rising Drug PricesU.S. Hospitals Still Prescribe Too Many Antibiotics: StudyBirth Control Pills Recalled Due to Danger of Unintended PregnancyNew Drugs Show Promise as First to Prevent MigraineMedication Adherence Up With Refill Synchronization ModelModified Vancomycin May Help Fight Bacterial ResistanceScientists Tweak Antibiotic to Boost Power Against 'Superbugs'New Cholesterol Fighting Meds Target Key GeneResearchers Say PDE5 Inhibitors Don't Cause MelanomaNearly a Third of Drugs Hit by Safety Issues After FDA ApprovalU.S. Moves to Avert Shortage of Yellow Fever VaccineOpioid Use by Iraq, Afghanistan War Vets Mirrors Rest of U.S.: StudyApril 29 Is National Prescription Drug Take Back DayERs Administering More Medications IntranasallyFDA Warns Against Children Taking Codeine, TramadolPhysicians Finding Ways to Work Around Cost of Rx MedicationsRuling Out Penicillin Allergy by Testing Inpatients Saves MoneyEpiPen Out-of-Pocket Costs More Than Doubled Over DecadeAACR: Regular Aspirin Use Linked to Lower Cancer MortalityFDA Approves Noctiva Nasal Spray for Nocturnal PolyuriaFDA Approves Odactra for House Dust Mite AllergiesHow Much Melatonin Is Really in That Supplement?Antidepressant Efficacy Varies for Depressive Symptom ClustersDo You Need an Antibiotic?'Off-Label' Antidepressants Common, But Where's the Evidence?Docs More Likely to Prescribe Antibiotics If Patients Expect ThemSimilar Adverse Event Risk for Typical, Atypical AntipsychoticsRx Adherence Reminders No More Effective at 'Fresh Start' DatesThink You're Allergic to Penicillin? Check AgainExcessive FDA Regulation Driving High Drug PricesOutcomes-Based Pricing Suggested for New, Costly DrugsPrices Skyrocket on Drugs Widely Used by Seniors: Report1 in 6 U.S. Adults Takes a Psychiatric Drug: StudyU.S. Doctors Still Over-Prescribing Drugs: SurveyWider Low-Dose Aspirin Use Would Save U.S. $692 Billion: StudyHealth Tip: Get the Facts About AntibioticsThese Medicines Often Send Americans to ERsHealth Tip: Be Aware of Drug and Food InteractionsCan Time-Release Capsules Replace Daily Pills?Prices of Generic Heart Failure Drugs Vary WidelyAmericans Fed Up With Soaring Drug Prices: HealthDay/Harris PollSaturday, Oct. 22 Is Drug Take Back DayHow Older People Can Head Off Dangerous Drug InteractionsCDC: Too Many Antibiotics Still Being Prescribed in U.S.Codeine Not Safe for Kids, Pediatricians WarnHealth Tip: Reading the Label on OTC MedicationsMylan to Offer Generic EpiPenSteep Rise in U.S. Drug Prices Tied to Patent Monopolies
Questions and AnswersVideosLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Depression & Related Conditions
Mental Disorders
Mental Health Professions

Mylan to Offer Generic EpiPen

HealthDay News
by -- Margaret Farley Steele
Updated: Aug 29th 2016

new article illustration

MONDAY, Aug. 29, 2016 -- A cheaper generic version of the emergency allergy treatment EpiPen will be made available within the next few weeks, manufacturer Mylan said Monday.

In the wake of mounting criticism over recent price hikes, the company said the generic version will be distributed by its U.S. subsidiary. It will have a list price of $300 for a two-pack, compared with $608 for the brand-name version. The generic version will be available in both 0.15 milligram (mg) and 0.30 mg strengths, the Associated Press reported.

EpiPens are used to treat anaphylaxis -- a severe, potentially fatal allergic reaction to insect bites and foods like nuts and eggs.

The auto-injection device, which contains the hormone epinephrine, expires after a year. Since most users need several -- one for home, and one for school or work, for example -- the costs can mount up.

With just one competitor, Mylan has a near monopoly on the device. Now, the company is being accused of price gouging after significantly increasing the EpiPen price in recent years.

The list price for the pack of two was a little more than $100 when Mylan first bought the device in 2007. Most of the increase -- from $265 to more than $600 -- has come in the last three years, The New York Times reported.

Health insurance doesn't necessarily help all people who need EpiPens, because those with high deductibles must pay almost the total price.

Some politicians have called for: Congressional hearings on the escalating pricing, an investigation by the Federal Trade Commission, and action by the U.S. Food and Drug Administration to increase competition by hastening approvals of competitors' products, the AP reported.

EpiPens have been marketed since the 1980s, and some observers have also questioned why Mylan still holds a patent. The patent applies to the device itself, not the active ingredient.

At least two companies are seeking approval to sell a rival brand or generic version of EpiPen in the United States, but none are likely to be available until later next year.

However, the compounding pharmacy Imprimis Pharmaceuticals said it may have a version available for individual patients in a few months. It said it would likely charge about $100 for two injectors, the AP reported.

More information

The American Academy of Pediatrics has more about treating anaphylaxis.